PL2533047T3 - Ccr4 jako cel terapeutyczny dla nowotworu - Google Patents
Ccr4 jako cel terapeutyczny dla nowotworuInfo
- Publication number
- PL2533047T3 PL2533047T3 PL12182790.1T PL12182790T PL2533047T3 PL 2533047 T3 PL2533047 T3 PL 2533047T3 PL 12182790 T PL12182790 T PL 12182790T PL 2533047 T3 PL2533047 T3 PL 2533047T3
- Authority
- PL
- Poland
- Prior art keywords
- ccr4
- cancer
- therapeutic target
- therapeutic
- target
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0718167A GB0718167D0 (en) | 2007-09-18 | 2007-09-18 | Cancer marker and therapeutic target |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2533047T3 true PL2533047T3 (pl) | 2016-11-30 |
Family
ID=38670078
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12183760T PL2535716T3 (pl) | 2007-09-18 | 2008-09-18 | Marker nowotworowy i cel terapeutyczny |
PL12182790.1T PL2533047T3 (pl) | 2007-09-18 | 2008-09-18 | Ccr4 jako cel terapeutyczny dla nowotworu |
PL08806315T PL2176664T3 (pl) | 2007-09-18 | 2008-09-18 | Ccr4 jako marker nowotworowy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12183760T PL2535716T3 (pl) | 2007-09-18 | 2008-09-18 | Marker nowotworowy i cel terapeutyczny |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08806315T PL2176664T3 (pl) | 2007-09-18 | 2008-09-18 | Ccr4 jako marker nowotworowy |
Country Status (11)
Country | Link |
---|---|
US (2) | US9134293B2 (pl) |
EP (3) | EP2176664B1 (pl) |
JP (2) | JP5774309B2 (pl) |
AU (1) | AU2008300413B2 (pl) |
CA (1) | CA2699702C (pl) |
DK (3) | DK2535716T3 (pl) |
ES (3) | ES2588507T3 (pl) |
GB (1) | GB0718167D0 (pl) |
PL (3) | PL2535716T3 (pl) |
RU (2) | RU2529797C2 (pl) |
WO (1) | WO2009037454A2 (pl) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
US11029313B2 (en) | 2008-09-26 | 2021-06-08 | The General Hospital Corporation | Method of treating cervical neoplasia in patients infected with human papilloma virus |
US9229004B2 (en) | 2008-09-26 | 2016-01-05 | The General Hospital Corporation | Methods for detecting and treating cancer |
GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
EP2580348B1 (en) * | 2010-06-14 | 2018-04-25 | Qiagen GmbH | Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples |
GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
JP6259764B2 (ja) * | 2011-10-24 | 2018-01-10 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | 炭酸脱水酵素関連マーカーおよびその使用 |
PT2785692T (pt) | 2011-12-01 | 2018-01-04 | Chemocentryx Inc | Anilinas substituídas como antagonistas do ccr(4) |
GB2512857A (en) * | 2013-04-09 | 2014-10-15 | Cancer Res Technology | Cancer biomarker |
MA39090B2 (fr) | 2013-11-06 | 2021-10-29 | Janssen Biotech Inc | Anticorps anti-ccl17 |
CN115925946A (zh) | 2014-05-28 | 2023-04-07 | 阿吉纳斯公司 | 抗gitr抗体和其使用方法 |
CA2962812A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject |
RU2718780C9 (ru) * | 2015-04-17 | 2020-07-08 | Эйсай Инк. | Способы лечения рака легкого |
CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
JP7177445B2 (ja) * | 2017-05-19 | 2022-11-24 | 真吾 前田 | Ccr4阻害による制御性t細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
EP0689606A1 (en) * | 1993-03-19 | 1996-01-03 | The Johns Hopkins University | ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE |
GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
US6245332B1 (en) | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
DE60134962D1 (de) | 2000-03-03 | 2008-09-04 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
CA2425259A1 (en) | 2000-10-11 | 2002-04-18 | Tularik, Inc. | Modulation of ccr4 function |
AU2002213466A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
NZ538347A (en) | 2000-10-18 | 2007-03-30 | Schering Ag | Use of antiprogestins for the induction of apoptosis in a cell |
CA2439279A1 (en) * | 2001-02-28 | 2002-09-06 | Protein Design Labs, Inc. | Chemokine receptors and disease |
US7144903B2 (en) | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
WO2003014153A2 (en) | 2001-08-10 | 2003-02-20 | Topigen Pharmaceutique Inc. | Cellular virus receptors and methods of use. |
EP1449850B9 (en) | 2001-08-31 | 2011-05-11 | Kyowa Hakko Kirin Co., Ltd. | Human cdr-grafted antibodies and antibody fragments thereof |
WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
AU2003291549A1 (en) | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
CA2516138A1 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
SE0301650D0 (sv) | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
WO2005023771A1 (ja) | 2003-09-05 | 2005-03-17 | Ono Pharmaceutical Co., Ltd. | ケモカインレセプターアンタゴニストおよびその医薬用途 |
JPWO2005035582A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Ccr4に特異的に結合する抗体組成物 |
ATE486611T1 (de) | 2003-12-04 | 2010-11-15 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
JP2007217282A (ja) | 2004-03-04 | 2007-08-30 | Astellas Pharma Inc | 置換ピリミジン誘導体 |
WO2005106471A2 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4) |
JP2007269629A (ja) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
RU2296328C1 (ru) * | 2005-09-21 | 2007-03-27 | Общество с ограниченной ответственностью "ГЕН" | Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
RU2518330C2 (ru) | 2006-02-14 | 2014-06-10 | Ноксон Фарма Аг | Нуклеиновые кислоты, связывающиеся с мср-1 |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
-
2007
- 2007-09-18 GB GB0718167A patent/GB0718167D0/en not_active Ceased
-
2008
- 2008-09-18 AU AU2008300413A patent/AU2008300413B2/en not_active Ceased
- 2008-09-18 ES ES12182790.1T patent/ES2588507T3/es active Active
- 2008-09-18 ES ES12183760.3T patent/ES2612690T3/es active Active
- 2008-09-18 DK DK12183760.3T patent/DK2535716T3/en active
- 2008-09-18 EP EP08806315.1A patent/EP2176664B1/en not_active Not-in-force
- 2008-09-18 ES ES08806315.1T patent/ES2443541T3/es active Active
- 2008-09-18 PL PL12183760T patent/PL2535716T3/pl unknown
- 2008-09-18 EP EP12183760.3A patent/EP2535716B1/en not_active Not-in-force
- 2008-09-18 RU RU2010123921/15A patent/RU2529797C2/ru not_active IP Right Cessation
- 2008-09-18 US US12/679,002 patent/US9134293B2/en not_active Expired - Fee Related
- 2008-09-18 PL PL12182790.1T patent/PL2533047T3/pl unknown
- 2008-09-18 DK DK08806315.1T patent/DK2176664T3/da active
- 2008-09-18 CA CA2699702A patent/CA2699702C/en not_active Expired - Fee Related
- 2008-09-18 DK DK12182790.1T patent/DK2533047T3/en active
- 2008-09-18 PL PL08806315T patent/PL2176664T3/pl unknown
- 2008-09-18 JP JP2010525420A patent/JP5774309B2/ja not_active Expired - Fee Related
- 2008-09-18 EP EP12182790.1A patent/EP2533047B1/en not_active Not-in-force
- 2008-09-18 WO PCT/GB2008/003160 patent/WO2009037454A2/en active Application Filing
-
2014
- 2014-07-14 RU RU2014128513A patent/RU2014128513A/ru not_active Application Discontinuation
-
2015
- 2015-06-30 JP JP2015131752A patent/JP6234967B2/ja not_active Expired - Fee Related
- 2015-08-11 US US14/823,755 patent/US10261099B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2533047B1 (en) | 2016-05-11 |
EP2535716A2 (en) | 2012-12-19 |
JP6234967B2 (ja) | 2017-11-22 |
US10261099B2 (en) | 2019-04-16 |
ES2588507T3 (es) | 2016-11-03 |
RU2010123921A (ru) | 2011-12-20 |
RU2014128513A (ru) | 2016-02-10 |
JP5774309B2 (ja) | 2015-09-09 |
RU2529797C2 (ru) | 2014-09-27 |
WO2009037454A3 (en) | 2009-05-07 |
AU2008300413B2 (en) | 2014-09-11 |
ES2443541T3 (es) | 2014-02-19 |
CA2699702A1 (en) | 2009-03-26 |
DK2176664T3 (da) | 2014-01-20 |
CA2699702C (en) | 2018-03-06 |
JP2010539508A (ja) | 2010-12-16 |
AU2008300413A1 (en) | 2009-03-26 |
EP2533047A1 (en) | 2012-12-12 |
US20100278844A1 (en) | 2010-11-04 |
JP2015212703A (ja) | 2015-11-26 |
GB0718167D0 (en) | 2007-10-31 |
EP2535716A3 (en) | 2013-03-13 |
DK2535716T3 (en) | 2017-02-13 |
WO2009037454A2 (en) | 2009-03-26 |
EP2176664A2 (en) | 2010-04-21 |
US9134293B2 (en) | 2015-09-15 |
US20160223572A1 (en) | 2016-08-04 |
ES2612690T3 (es) | 2017-05-18 |
EP2535716B1 (en) | 2016-11-02 |
PL2176664T3 (pl) | 2014-04-30 |
EP2176664B1 (en) | 2013-11-06 |
DK2533047T3 (en) | 2016-08-22 |
PL2535716T3 (pl) | 2017-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2533047T3 (pl) | Ccr4 jako cel terapeutyczny dla nowotworu | |
EP2211620A4 (en) | THERAPEUTIC COMPOUNDS | |
EP2127671A4 (en) | THERAPEUTIC AGENT AGAINST CANCER | |
HK1137158A1 (en) | Formulations for cancer treatment | |
HK1151734A1 (en) | Therapeutic for hepatic cancer | |
GB0813087D0 (en) | Therapeutic compounds | |
GB0716532D0 (en) | Therapeutic compounds | |
EP2164324A4 (en) | THERAPEUTIC COMPOUNDS | |
HK1142774A1 (en) | Therapeutic pyrazolonaphthyridine derivatives | |
EP2185568A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0821537D0 (en) | Therapeutic target | |
GB0700645D0 (en) | Targets for disease therapy | |
EP2099303A4 (en) | THERAPEUTIC COMPOSITIONS ON TETRAHYDROISOCHINOLINE BASE FOR CANCER THERAPY | |
GB0707556D0 (en) | Treatment for cancer | |
GB0702862D0 (en) | Therapeutic compounds | |
GB0708188D0 (en) | Therapeutic compounds | |
GB0706538D0 (en) | Cancer therapeutic | |
GB0700654D0 (en) | Targets for disease therapy | |
GB0700643D0 (en) | Targets for disease therapy | |
GB0700647D0 (en) | Targets for disease therapy | |
GB0700648D0 (en) | Targets for disease therapy | |
GB0700655D0 (en) | Targets for disease therapy | |
GB0700650D0 (en) | Targets for disease therapy | |
GB0700651D0 (en) | Targets for disease therapy | |
GB0700644D0 (en) | Targets for disease therapy |